IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML
Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.
Related Articles
Biomarker-Directed Radiotherapy in Breast Cancer
This narrative review explores the potential of biomarker-directed personalized radiotherapy approaches.
Maintenance Galinpepimut-S Appears Effective and Safe in AML in Second CR
Galinpepimut-S demonstrated early efficacy signals in patients with acute myeloid leukemia in second complete remission or later.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
A retrospective study of autoSCT outcomes in older adults with R/R classic Hodgkin lymphoma
Sanjal Desai, MBBS, Mayo Clinic, Rochester, MN, presents the findings of a multi-center international retrospective study that investigated the outcomes of autologous stem cell transplantation…
ALASCCA: adjuvant aspirin in colorectal cancer
The randomized ALASCCA trial (NCT02647099) investigated the effect of low-dose aspirin in patients with stage II and III colorectal cancer and PIK3CA mutations. Anna Martling,…
Conference
Please sign in with your EORTC event profile credentials in order to register for the Y-ECI Webinar(s). If you do not have a profile yet,…
Comprehensive characterization of MCL‐1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes
MCL-1, an anti-apoptotic protein required for intestinal homeostasis, has been associated with chemoresistance in colorectal cancer. This study provides novel insights into the molecular profile…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!